Search - tctmd.com

Displaying 161 - 180 of 223

Sort: Relevancy | Date

News Daily News

More Missing MIs, Late Complications Blamed on COVID-19 in Italy and California

Shelley Wood

May 22, 2020

News Daily News

LV Mass Regression After TAVR Linked to Better Long-term Outcomes

Michael O'Riordan

May 13, 2020

News Daily News

Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM

Shelley Wood

May 11, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Daily News

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

Michael O'Riordan

January 22, 2020

News Daily News

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Michael O'Riordan

October 17, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Opinion Off Script

Off Script: Implicit Bias Can Be a Matter of Life and Death—Let’s Do Something About It

Quinn Capers IV, MD

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Features ESC Heart Failure 2019

At the ESC Heart Failure Congress, Some COAPT Converts—and Some Pushback

Shelley Wood

May 30, 2019

News Daily News

Multisociety Consensus Statement Tackles the Classification of Heart Valve Centers

L.A. McKeown

April 19, 2019

News Daily News

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Michael O'Riordan

April 15, 2019

News Daily News

FDA Grants Approval to TherOx for Supersaturated Oxygen Therapy in LAD STEMI

L.A. McKeown

April 04, 2019

News Daily News

Unplanned Readmission Within 6 Months Affects 25% of PCI Patients in the US

L.A. McKeown

March 28, 2019

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

Advertisement

More Missing MIs, Late Complications Blamed on COVID-19 in Italy and California

LV Mass Regression After TAVR Linked to Better Long-term Outcomes

Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

Off Script: Implicit Bias Can Be a Matter of Life and Death—Let’s Do Something About It

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

FDA Expands TAVR Indication to Low-Risk Patients

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

At the ESC Heart Failure Congress, Some COAPT Converts—and Some Pushback

Multisociety Consensus Statement Tackles the Classification of Heart Valve Centers

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

FDA Grants Approval to TherOx for Supersaturated Oxygen Therapy in LAD STEMI

Unplanned Readmission Within 6 Months Affects 25% of PCI Patients in the US

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content